Printable version
Send by mail
Use eCRF in your future studies, Altizem can help you !
02/09/2010 - 15:01Easy, fast, reliable use eCRF in your future studies : clinical, marketing, epidemiologic and medico-economic.
Altizem can help you and we propose you an eCRF answering to your needs.
Read moreRoche Releases Results Of First Phase III Study For Taspoglutide
10/30/2009 - 18:21Roche has released the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research.
The company said that the phase III study, T-EMERGE 2 met its primary endpoint of change in HbA1c (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD).
Read more